PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 30, 2026

Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).

View Full Paper
Ask AI
Bookmark
Share

Authors

AYAycan YükselDKDilek KaradoğanNHNur Hürsoy

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved oxygen saturation and exercise capacity in interstitial lung disease patients, suggesting effective management with methylprednisolone.

Key Points

  • This research aims to evaluate the efficacy of methylprednisolone in managing post-COVID-19 interstitial lung disease.
  • Conducted as a randomized trial (STERCOV-ILD)
  • Compared methylprednisolone treatment to the natural course of the disease
  • Assessed outcomes including oxygen saturation, FVC, and exercise capacity
  • Methylprednisolone improved oxygen saturation levels
  • Increased exercise capacity was observed
  • Enhanced FVC and radiological resolution were significant

Cite This Study

Yüksel et al. (2026) studied this question.

synapsesocial.com/papers/69c9c553f8fdd13afe0bd45chttps://doi.org/10.36141/svdld.2026.17022
View Full Paper
Ask AI
Bookmark
Share